Reviewing Flashcards
Cryptogenic organizing pneumonia (COP) CLINICAL FEATURES
Same as bronchiolitis obliterans organizing pneumonia (BOOP)
Malaise, fevers and cough.
Their cough may be dry or productive.
Sputum may be of clear or discolored.
Typically discloses inspiratory crackles, but the exam can be normal.
Fifth to sixth decade of life
Cryptogenic organizing pneumonia Risk factors:
Rheumatoid arthritis
Granulomatosis with polyangiitis and polymyositis
Dermatomyositis
After radiation exposure to lung
Secondary to some medications
Smoking is not considered a risk factor
Cryptogenic organizing pneumonia (COP) Investigations
CXR
FBE, ESR, and CRP
Torax CT
PFT
Bronchoscopy with bronchoalveolar lavage
Lung Biopsy
Diagnosed only after exclusion of any other possible etiology
Cryptogenic organizing pneumonia (COP) Differential
Disruption of the normal lung architecture should also lead to consideration of an alternative diagnosis like Usual Interstitial Pneumonia (UIP) or other Idiopathic Pulmonary Fibrosis (IPF).
Cryptogenic organizing pneumonia (COP) Chest X-ray features
Single or multifocal air space opacities.
Patchy diffuse consolidations mostly involve bilateral lower zones.
Nodular opacities: Migratory, irregular, or linear.
Pleural effusions can also be seen.
Cryptogenic organizing pneumonia (COP) Bloods results
White cell count is typically elevated with neutrophilia.
ESR and CRP are commonly elevated.
When COP is suspected then testing for autoimmune diseases should be undertaken.
Cryptogenic organizing pneumonia (COP) Torax CT features
Atoll sign, also known as the reverse halo sign: Dense outer rim of consolidation around a focal ground-glass opacity.
Non-sensitive or specific. Can be seen in other infectious and inflammatory conditions.
Cryptogenic organizing pneumonia (COP) Pulmonary Function Test features
Typically reveals a restrictive defect with diffusion impairment
Cryptogenic organizing pneumonia (COP) Bronchoscopy with bronchoalveolar lavage Features
Performed to rule out infections, pulmonary hemorrhage, and malignancy.
In COP: Mixed cellularity with neutrophils, lymphocytes, and eosinophils. Significant lymphocyte elevation (approximately 40%) is typical, and CD4/CD8 ratio reveals CD8 predominance.
Cryptogenic organizing pneumonia (COP) Lung Biopsy Features
DEFINITIVE DIAGNOSE: Formation of organized buds of granulation tissue obstructing the alveolar lumen and bronchioles. Leakage of plasma proteins into the alveolar space, results as organized plugs of intraluminal granulation tissue are known as Masson bodies
IMPORTANT NOTE: Treatment can be started without a lung biopsy, after discussion with the patient.
Cryptogenic organizing pneumonia (COP) TREATMENT
Prednisone 1 mg/kg per day and weaning over 6 to 12 months
Second-line agents Cyclophosphamide and Cyclosporine A
Cryptogenic organizing pneumonia (COP) Prognosis
Generally excellent with a good response to systemic corticosteroids
PNEUMONIA MOS COMMON CAUSES (Microorganisms)
Neonatal Respiratory Distress DIFFERENTIALS
ASTHMA: Salbutamol dose
ASTHMA: Management of mild-moderate ATTACK
ASTHMA: Management of SEVERE ATTACK
TUBERCULOSIS DIAGNOSE ALGORITHM
Erythema nodosum SLIDE
Tuberculosis: Ghon focus
DRUGS that produce gynecomastia
Ostoporosis RISK FACTORS
Diet- low in calcium
Low BMI < 19
Lack of exercise
Inadequate exposure to sunlight
SAD and excessive coffee intake
Medications: glucocorticoids, anticonvulsants (phenothiazines), GnRh, aromatase inhibitors (Letrozole, Anastrozole, Exemestane), heparin, Depo, thiazolidinedions (glitazones), PPI’s
Medical conditions: hyperthyroidism, hyperparathyroidism, chronic liver or renal disorders, rheumatoid arthritis, coeliac disease
Menopause
Family history
Ostoporosis First Investigation
25 hydroxy Vitamin D
Ostoporosis Best Investigation
DEXA Scan (Don’t take Ca 24 hours before)
- T-score:
> -1: Normal, - 0.9 to -2.4: Osteopenia
< -2.5: Osteoporosis - Z score: ≤ -2: Investigation for underlying causes
OSTEOPENIA CRITERIA FOR TREATMENT
T score between -1 and -2.5 without minimal trauma fracture
Treat with calcium and Vitamin D supplementation and lifestyle modifications:
1200- 1500 mg/day of calcium
800- 2000 IU/day of Vitamin D
Osteoporosis CRITERIA FOR TREATMENT
Any man or woman with spine or hip fractures after minimal trauma even if the T score is more than -2.5. Treatment may be initiated without confirmation of low bone mineral density.
No fracture but score < or equal to -2.5 if risk factors are present
Osteoporosis due to secondary causes
Treatment with medications has to be started along with Calcium and Vitamin D supplementation
1200- 1500 mg/day of calcium
800- 2000 IU/day of Vitamin D
Notes: Medications increase bone density in the hip approximately by 1-3% and in the spine by 4-8% over 3-4 years
Osteoporosis FIRST-LINE Treatment
- Bisphosphonates
- Alendronate
- Risedronate
- Zoledronic Acid - Denosumab
- Strontium ranelate
- Raloxifene
- MHT
Osteoporosis Treatment: BISPHOSPHONATES General Features
- Decrease bone loss and increase mineral density.
- Measure Vit D and RFT before starting the treatment.
- Useful for vertebral & non-vertebral fractures.
- Contraindicated in pregnancy because it’s teratogenic.
- Side Effects: GI discomfort, oesophagitis, and jaw necrosis
Osteoporosis FIRST-LINE Treatment: BISPHOSPHONATES Alendronate & Risedronate
- Alendronate - weekly dose
- Risedronate - daily/weekly/monthly
For 5 to 10 years in postmenopausal women.
Osteoporosis FIRST-LINE Treatment: BISPHOSPHONATES Zoledronic Acid
Annual infusion for a maximum of 3 years.
Used if patients have Oesophagitis.
Vitamin D levels should be corrected to 50nmol/L before starting the treatment.
Osteoporosis FIRST-LINE Treatment: Denosumab
- Monoclonal antibody against osteoclast.
- Given as 6 monthly injections subcutaneously for 36 months.
- No gastrointestinal side effects.
- But increases hypocalcemia.
Osteoporosis FIRST-LINE Treatment: Strontium ranelate
Given orally 2 grams/day.
Should not be given with calcium supplements.
Reserved for severe osteoporosis because can cause MI
- Contraindications:
- DVT
- Prolonged immobilisation
Osteoporosis FIRST-LINE Treatment: Raloxifene
- Selective estrogen receptor modulator
- Oestrogen-like effect on bone but antagonistic for uterus and breast.
- Can be considered as second-line treatment for postmenopausal women with osteoporosis at risk of breast cancer.
- Reduces risk of vertebral fractures.
Osteoporosis FIRST-LINE Treatment: MHT
In peri or postmenopausal women with osteoporosis associated with other menopausal symptoms
Osteoporosis SECOND-LINE Treatment
Teriparatide:
- Is a recombinant parathyroid hormone.
- Stimulates bone-forming cells.
- Only if other treatments fail.
- Given as daily injections subcutaneously for 18 months.
INDICATIONS: > 1 symptomatic new fracture after 12 months of biphosphonate or if T score is ≤-3
OSTEOPOROSIS
Treatment for people with special circumstances: Corticosteroid therapy
All people above 50 years on corticosteroid therapy of 7.5 mg/day for at least 3 months with a T score of -1.5 or less have to be given bisphosphonates for the duration of therapy.
- First-line: Alendronate and risedronate with adjuvant Calcium and Vit D.
- Second-line: Zoledronic acid.
OSTEOPOROSIS
Treatment for people with special circumstances: Renal impairment
Raloxifene or Denosumab.
Osteoporosis Treatment Follow-up
Repeat DEXA in 2 years.
Every year if medication is changed, termination of the treatment or high-risk patient.
Osteopenia Follow-up
Repeat DEXA every 2 - 5 years
CTG Baseline rate of the fetal heart
Normal: 110-160 bpm
Fetal tachycardia: > 160 bpm
Fetal bradycardia: < 110 bpm.
Severe prolonged: < 80 bpm for more than 3 minutes (severe hypoxia)
CTG Fetal tachycardia CAUSES
- Fetal hypoxia
- Chorioamnionitis
- Hyperthyroidism
- Fetal or maternal anaemia
- Fetal tachyarrhythmia
CTG Fetal Bradycardia CAUSES
100-120 bpm:
1. Postdate gestation
2. Occiput posterior or transverse presentations
Severe prolonged:
1. Prolonged cord compression
2. Cord prolapse
3. Epidural and spinal anesthesia
4. Maternal seizures
5. Rapid fetal descent
CTG Variability Criteria
Normal: 5-25 bpm (Reassuring)
Non-reassuring:
Less than 5 bpm for 50 min
More than 25 bpm for 25 min
Abnormal:
Less than 5 bpm for more than 50 min
More than 25 bpm for more than 25 m
Sinusoidal
CTG Reduced variability CAUSES
- Fetal sleeping: this should last no longer than 40 minutes (this is the most common cause)
- Fetal acidosis (due to hypoxia): more likely if late decelerations are also present Fetal tachycardia
- Drugs: opiates, benzodiazepines, methyldopa and magnesium sulphate
- Prematurity: variability is reduced at earlier gestation (<28 weeks)
- Congenital heart abnormalities
CTG Accelerations Criteria
Accelerations are an abrupt increase in the baseline fetal heart rate of greater than 15 bpm for greater than 15 seconds
The presence of accelerations is reassuring
Accelerations occurring alongside uterine contractions is a sign of a healthy fetus.
CTG Decelerations Definition
Abrupt decrease in the baseline fetal heart rate of greater than 15 bpm for greater than 15 seconds.
CTG Early Deceleration Features
Start when the uterine contraction begins and recover when uterine contraction stops.
Physiological due to increased fetal intracranial pressure
CTG Variable Deceleration Features
Rapid fall in baseline fetal heart rate with a variable recovery phase.
Variable in their duration and may not have any relationship to uterine contractions.
CTG Variable Deceleration CAUSES
- Reduced amniotic fluid volume
- Umbilical cord compression
CTG Shoulders of Variable Deceleration MEANING
Accelerations before and after a variable deceleration. Indicates the fetus is not yet hypoxic and is adapting to the reduced blood flow. Without the shoulders, suggests the fetus is becoming hypoxic
CTG Variable Deceleration 1st management
Variable decelerations can sometimes resolve if the mother changes position
The presence of persistent variable decelerations indicates the need for close monitoring.
CTG: Late deceleration Features
Begin at the peak of uterine contraction and recover after the contraction ends.
Indicates: Insufficient blood flow through the uterus and placenta
(Danger of fetal hypoxia and acidosis).
CTG: Late deceleration CAUSES
o Maternal hypotension
o Pre-eclampsia
o Uterine hyper-stimulation
CTG: Late deceleration MANAGEMENT
The presence of late decelerations is taken seriously and foetal blood sampling for pH is indicated.
If foetal blood pH is acidotic it indicates significant foetal hypoxia and the need for emergency C-section.
CTG: Prolonged deceleration
A deceleration that lasts more than 2 minutes.
If it lasts between 2-3 minutes it is classed as non-reassuring
If it lasts longer than 3 minutes it is immediately classed as abnormal
Action must be taken quickly: Fetal blood sampling or emergency C-section
CTG: ABNORMAL Deceleration Features
Variable decelerations with any concerning characteristics in over 50% of contractions for 30 minutes (or less if any maternal or fetal clinical risk factors).
Late decelerations for 30 minutes (or less if any maternal or fetal clinical risk factors).
Acute bradycardia, or a single prolonged deceleration lasting 3 minutes or more.
CTG Sinusoidal pattern FEATURES
This type of pattern is rare, however if present it is very serious.
It is associated with high rates of foetal morbidity & mortality
It is described as:
o A smooth, regular, wave-like pattern
o Frequency of around 2-5 cycles a minute
o Stable baseline rate around 120-160 bpm
o No beat to beat variability
CTG Sinusoidal pattern INDICATES
o Severe foetal hypoxia
o Severe foetal anaemia
o Foetal/maternal haemorrhage
Immediate C-section is indicated
Diabetes Mellitus Diagnose
FBG:
- If ≥7: DM
- If 5.5-6.9 —->OGTT
OGTT
- If ≥ 11.1: DM
- If 7.8-11Retest in a year
- if ≤7.7: Retest in 3 years
HbA1c:
- If ≥6.5: DM
- If 6-6.4: retest in 1 year
- If ≤5.9 retest in 3 years
Diabetes Mellitus Diagnose FLOW CHART
Gestational Diabetes Diagnose
Gestational Diabetes Risk factors
Diabetes Mellitus Screening
People with known impaired fasting glucose/glucose tolerance (‘prediabetes’)
Age >40 years
> 30 years: family history (first-degree relative with T2D), obesity (BMI >30), high-prevalence ethnic groups
Age >18 years in Aboriginal and Torres Strait Islander people
Previous gestational diabetes
People on long-term steroids or antipsychotics
Polycystic ovarian syndrome, especially if overweight
Previous cardiovascular event
The optimal frequency is every 3 years from age 40 years using AUSDRISK
If the score is ≥12, do fasting blood glucose or HbA1c.
Screen annually in very high-risk groups (including Aboriginal and Torres Strait Islander people and those with prediabetes)
Diabetes Mellitus T2 Treatment: Metformin side effects
*gastrointestinal adverse effects
*vitamin B12 deficiency
*lactic acidosis (rare)
CI: Renal Impairment GFR< 30 and liver impairment
Diabetes Mellitus T2 Treatment: Thiazolidinediones
GLITAZONE
Side Effects:
Weight gain
Dyslipidemia, CV disease
Osteopenia
Pioglitazone:
Risk for bladder cancer
Rosiglitazone:
Edema —>CHF
MI, Stroke
Diabetes Mellitus T2 Treatment: SGLT2
GLIFOZIN
dapagliflozin
empagliflozin
ertugliflozin
Advantages:
weight loss
reduce the rate of secondary cardiovascular events, including
overall mortality
reduce blood pressure
slow the progression of kidney disease
Side effects:
Genital infections (candida)
UTI
reversible increase in creatinine
volume depletion (rare)
diabetic ketoacidosis (uncommon), which may occur without hyperglycemia
Diabetes Mellitus T2 Treatment: Sulfonylureas
IDE
gliclazide
glipizide
glibenclamide
glimepiride
Side effects:
HYPOGLYCEMIA
Weight gain
Dermatological allergic reactions
Diabetes Mellitus T2 Treatment: DPP-4 inhibitors
GLIPTINE
alogliptin
linagliptin
saxagliptin (CI Heart failure)
sitagliptin
vildagliptin
Weith loss
avoid in patients with acute pancreatitis or history of pancreatitis
Side effects:
Headache
Mild respiratory and urinary infections
Weight neutral
Contraindications in Pregnancy and breastfeeding
Diabetes Mellitus T2 Treatment: GLP-1 receptor agonists
TIDE
dulaglutide
exenatide
liraglutide
Subcutaneous administration
Advantages:
weight loss
improve postprandial glucose control
reduce the rate of secondary cardiovascular events, including
overall mortality (liraglutide)
slow the progression of kidney disease (dulaglutide, liraglutide)
CI:
* Acute pancreatitis or history of pancreatitis
* Family history of medullary thyroid cancer or multiple
endocrine neoplasia syndrome type 2 (liraglutide)
* Severe kidney impairment (dulaglutide, exenatide)
* End-stage kidney disease (liraglutide)
MASTITIS Management
∗ Continue breast feeding from affected breast
∗ Place hot washers over breast before starting to feed and cold packs after feeding
∗ Antibiotics: Dicloxacillin Flucloxacillin Cephalexin for 5 days
∗ Analgesics
∗ Check breast feeding technique
∗ Review in 24- 48 h
∗ Basic blood tests and U/S if doubtful of breast abscess or in 48
hours if mastitis is not responding to antibiotics
∗ If Candidial mastitis-Fluconazole orally
CAUSES OF POSTPARTUM FEVER
Contraindications for Tocolisis
Tetanus prophylaxis
Common causes of pneumonia by ages
Alcohol withdrawal, hallucinosis and delirium tremens timings
Cellulitis Treatment
Chronic otitis media in aboriginal treatment
Acute otitis media treatment
RHEUMATIC FEVER JONES CRITERIA
paracetamol intoxication protocol
Melanoma excision margins
NEPHRO: Genetic disorders
Testicular tumors